Related Experiment Video
Updated: Dec 11, 2025
06:30
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
Published on: May 23, 2025
680
Tofacitinib in recalcitrant scleritis: First case report from India
Richa Pyare1, Viswanath Kaushik2, Parthopratim Dutta Majumder1
1Department of Uvea, Sankara Nethralaya, Chennai, Tamil Nadu, India.
Indian Journal of Ophthalmology
|August 23, 2020
Summary
Necrotizing scleritis, an inflammatory eye condition, may not respond to standard treatments. Tofacitinib, a Janus kinase (JAK) inhibitor, showed significant improvement in a patient refractory to conventional immunosuppressive therapy.
Area of Science:
- Ophthalmology
- Rheumatology
- Immunology
Background:
- Necrotizing scleritis is a severe inflammatory eye disease.
- Conventional immunosuppressive therapies (e.g., mycophenolate mofetil, corticosteroids) are often first-line treatments.
- Some patients exhibit refractory disease despite standard care.
